CureVac NV
June 16, 2025
Company Presentation
Oncology
We are pioneering the development of a completely new class of drugs based on the messenger RNA (mRNA). The basic principle is the use of this molecule as a data carrier for information, with the help of which the body itself can produce its own active substances to combat various diseases. It all began with an unexpected discovery. CureVac’s founder, Dr. Ingmar Hoerr (a doctoral student at the time), discovered that when it was administered directly into tissue, the historically unstable biomolecule mRNA could be used as a therapeutic vaccine or agent after optimization—no complicated reformulations or molecular packaging needed. With a single discovery, CureVac opened the world up to the potential of mRNA to treat diseases and create vaccines. Officially founded in 2000, CureVac is the world’s first company to successfully harness mRNA for medical purposes—because we saw opportunities where others saw obstacles.
Company HQ City:
Tuebingen
Company HQ State:
Tuebingen
Company HQ Country:
Germany
Year Founded:
2000
Lead Product in Development:
mRNA Vaccines
CEO
Alexander Zehnder, MD
Year Founded
2000
Development Phase of Lead Product
Phase I
Number of Unlicensed Products Looking for Licensing
4+
Exchange
NASDAQ
Ticker
CVAC
When you expect your next catalyst update?
Phase I readout, IND filing for programs, litigation updates,
What is your next catalyst (value inflection) update?
2H 2025
Website
https://www.curevac.com/en/
Primary Speaker
.jpg)
)
)
)
)
){kind=logo}
)
){kind=logo}
)
){kind=logo}